Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Promoter Methylation of Four Tumor Suppressor Genes in Human Papillary Thyroid Carcinoma Publisher



Khatami F1 ; Larijani B2 ; Heshmat R1 ; Nasiri S3 ; Saffar H4 ; Shafiee G1 ; Mossafa A3 ; Tavangar SM1, 4
Authors

Source: Iranian Journal of Pathology Published:2019


Abstract

Background & Objective: Papillary thyroid cancer (PTC) is considered to be the most common type of thyroid malignancies. Epigenetic alteration, in which the chromatin conformation and gene expression change without changing the sequence of DNA, can occur in some tumor suppressor genes and oncogenes. Methylation is the most common type of epigenetic alterations that can be an excellent indicator of PTC invasive behavior. Methods: In this research, we determined the promoter methylation status of four tumor suppressor genes (SLC5A8, RASSF1, MGMT, and DNMT1) and compared the results of 55 PTC cases with 40 goiter patients. For methylation, we used the methylation-sensitive high resolution melting (MS-HRM) assay technique. The resulting graphs of each run were compared with those of 0%, 50%, and 100% methylated controls. Results: Our data showed that the promoter methylation of SLC5A8, Ras association domain family member 1(RASSF1), and MGMT were significantly different between PTC tissue and goiter with P-value less than 0.05. The most significant differences were observed in RASSF1; 77.2% of hyper-methylated PTC patients versus 15.6% hyper-methylated goiter samples (P<0.001). Conclusion: RASSF1 promoter methylation can be a PTC genetic marker. RASSF1 promoter methylation is under the impact of the methyltransferase genes (DNMT1 and MGMT), protein expression, and promoter methylation. © 2019, Iranian Society of Pathology. All rights reserved.
Other Related Docs
5. Liquid Biopsy in Thyroid Cancer: New Insight, International Journal of Hematology-Oncology and Stem Cell Research (2018)
6. A Review of Driver Genetic Alterations in Thyroid Cancers, Iranian Journal of Pathology (2018)
10. Liquid Biopsy As a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations, International Journal of Molecular and Cellular Medicine (2019)
11. Personalized Treatment Options for Thyroid Cancer: Current Perspectives, Pharmacogenomics and Personalized Medicine (2019)
18. Adrenal Collision Tumor Composed of Pheochromocytoma and Diffuse Large B-Cell Lymphoma: A Case Report, International Journal of Hematology-Oncology and Stem Cell Research (2018)
19. Circulating Tumor Dna (Ctdna) in the Era of Personalized Cancer Therapy, Journal of Diabetes and Metabolic Disorders (2018)
20. A Review on the Molecular Pathology of Epithelial Thyroid Tumors, Journal of Isfahan Medical School (2018)